Impact of Human Growth Hormone on Plasma Lipoprotein Concentrations

Summary

To evaluate whether the moderately elevated human growth hormone concentration, seen in insulin dependent diabetic patients, has any impact on lipoproteins, human growth hormone was given to nondiabetic persons in doses which would bring their plasma human growth hormone concentration up in the same level as seen in insulin dependent diabetic patients. After one week of treatment with human growth hormone we found total plasma triglyceride to be significantly raised (0.98 mmol/l ± 0.28 mmol/l (mean ± SD) before versus 1.27 mmol/l ± 0.38 mmol/l (mean ± SD) after treatment). Very low density lipoprotein (VLDL) was separated into two fractions (VLDL-1 and VLDL-2) of which VLDL-2 is regarded as a VLDL-remnant which is suggested to be of importance for development of atherosclerosis. After one week of human growth hormone treatment there were no changes in VLDL-1 concentrations whereas a significant raise in VLDL-2 triglyceride and VLDL-2 cholesterol was seen.

Key-Words

Diabetes - Human Growth Hormone - Lipoproteins - Very Low Density Lipoprotein - Diabetic Angiopathy